• Innovative Eye Science

    Your vision is our focus

    Select Video
  • Play
    Select Video

At Inotek, we're working to define the future of glaucoma treatment.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.

Use the links above to view videos of our key leaders and contributors discussing Inotek's mission, vision, and the potential therapeutic value of our lead product candidate, trabodenoson.

A New Class of Glaucoma Therapy

Our most advanced product candidate, trabodenoson, is a highly selective adenosine mimetic and the first potential treatment for glaucoma of its kind.

Adenosine is an important molecule occurring naturally in the body that participates in a wide variety of physiological and pathological processes. Inotek’s scientists have deconstructed adenosine’s complex biology to isolate the protective activity of the molecule, and subsequently to build it into novel therapeutics.

Read More >


INSERTING and REPLACING Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases

- Company to Leverage Lentiviral and AAV Gene Therapy Platforms to Target Rare Genetic Diseases - - Transaction to Advance Rocket’s Growing Pipeline; Up to Four Clinical Trials to Begin in 2018 – - Proof of Concept Data Expected in 2018 for One or More Clinical Programs Focused on Rare Blood Disorders:...

Read More >